Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer?

Nature Clinical Practice Oncology volume 4, pages 398–399 (2007)Cite this article

boxed-textGeyer CE et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733–2743

Background

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Slamon DJ et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

    Article  CAS  Google Scholar 

  2. Valabrega G et al. (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2 overexpressing breast cancer. Ann Oncol [doi: 10.1093/annonc/mdl475]

  3. Montemurro F et al. (2006) Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 11: 318–324

    Article  CAS  Google Scholar 

  4. Gomez HL et al. (2006) Updated biomarker results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer [abstract #1090]. Breast Cancer Res Treat 100 (Suppl): S68

    Google Scholar 

  5. Xia W et al. (2007) Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 67: 1170–1175

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. F Montemurro is a Medical Oncologist of the University Division of Medical Oncology and Haematology Institute for Cancer Research and Treatment (IRCC), Candiolo, Torino, Italy.,

    Filippo Montemurro

  2. M Aglietta is Head of the University Division of Medical Oncology and Haematology Institute for Cancer Research and Treatment (IRCC), Candiolo, Torino, Italy. M Aglietta is also a Full Professor of Oncology at the University of Turin, Italy.,

    Massimo Aglietta

Authors
  1. Filippo Montemurro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Massimo Aglietta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Filippo Montemurro.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Montemurro, F., Aglietta, M. Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer?. Nat Rev Clin Oncol 4, 398–399 (2007). https://doi.org/10.1038/ncponc0849

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0849

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing